基于酞嗪酮类PARP抑制剂结构修饰的国内专利技术综述  

Patent Overview of Phthalazinone-type PARP Inhibitors Structural Modification Based on Patented Technologies in China

作　　者：李伟[1] 李娜 严华[1] LI Wei;LI Na;YAN Hua(Patent Examination Cooperation Center of the Patent Office, CNIPA, Beijing 100160;Department of Gastroenterology, Seventh Medical Center of PLA General Hospital, Beijing 100700, China)

机构地区：[1]国家知识产权局专利局专利审查协作北京中心,北京100160 [2]中国人民解放军总医院第七医学中心消化内科,北京100700

出　　处：《广州化工》2019年第9期34-40,共7页GuangZhou Chemical Industry

摘　　要：PARP是癌症治疗的一个新靶点,相关抑制剂的研究已逐渐成为企业和科研人员重点关注的方向。奥拉帕利是在国内上市的酞嗪酮类PARP抑制剂。通过对国内申请所涉及的酞嗪酮类PARP抑制剂的结构修饰现状进行专利技术分析,获取了该类药物的申请量、专利分布以及申请人的信息,分析了专利申请中专利技术发展过程,分类概括了酞嗪酮类化合物结构修饰的方法。PARP represents an important novel target in cancer therapy, while the research of PARP inhibitors is a highly concerned direction for relevant companies and researchers. Olaparib is a domestic market drug of phthalazinone-type PARP inhibitors. The domestic patent application of phthalazinone-type PARP inhibitors structural modification to get the application trend, the distribution of patents and the information of applicants was analyzed. The whole technological process was brought out and the main methods of structural modification of phthalazinone-type PARP inhibitors were summarized.

关 键 词：PARP抑制剂 酞嗪酮 奥拉帕利 专利技术 

分 类 号：R914.4[医药卫生—药物化学]